When every minute matters, Access BNP is the right assay for you
Laboratories can help clinicians deliver patient care with confidence for all stages of heart failure (HF) with Access BNP, a highly sensitive and specific assay that aids clinicians in the:
- Diagnosis and assessment of severity of congestive HF
- Risk stratification of patients with HF and acute coronary syndrome (ACS)
The Access BNP is a high-quality assay with an analytical sensitivity of 1 pg/mL. The assay demonstrates general specificity of 98%. BNP results less than or equal to 100 pg/mL are representative of normal values in patients without HF. BNP results greater than 100 pg/mL are considered abnormal and suggestive of patients with HF.
Beckman Coulter has produced BNP since 2003, which clinical laboratories have used under the brand name Quidel® Triage BNP Test for the Beckman Coulter Access Family of Immunoassay Systems. Beckman Coulter announced signing of a contract with Quidel on July 26, 2021*, and will eventually sell the product under the brand name Access BNP directly and through distributors to customers who will experience the same product quality, while gaining the convenience of direct contracting, ordering and support from Beckman Coulter.